148 related articles for article (PubMed ID: 23121406)
1. Chemically modified tetracyclines as inhibitors of MMP-2 matrix metalloproteinase: a molecular and structural study.
Marcial BL; Sousa SF; Barbosa IL; Dos Santos HF; Ramos MJ
J Phys Chem B; 2012 Nov; 116(46):13644-54. PubMed ID: 23121406
[TBL] [Abstract][Full Text] [Related]
2. Structural and dynamics analysis of matrix metalloproteinases MMP-2 complexed with chemically modified tetracyclines (CMTs).
Marcial BL; Sousa SF; Santos HF; Ramos MJ
J Biomol Struct Dyn; 2014 Dec; 32(12):1907-18. PubMed ID: 24125013
[TBL] [Abstract][Full Text] [Related]
3. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
[TBL] [Abstract][Full Text] [Related]
4. Chemically modified tetracyclines stimulate matrix metalloproteinase-2 production by periodontal ligament cells.
Bildt MM; Snoek-Van Beurden AM; DeGroot J; Van El B; Kuijpers-Jagtman AM; Von den Hoff JW
J Periodontal Res; 2006 Oct; 41(5):463-70. PubMed ID: 16953823
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics.
Hou T; Zhang W; Xu X
J Comput Aided Mol Des; 2002 Jan; 16(1):27-41. PubMed ID: 12197664
[TBL] [Abstract][Full Text] [Related]
6. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.
Di Pizio A; Laghezza A; Tortorella P; Agamennone M
ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
[TBL] [Abstract][Full Text] [Related]
8. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases.
Sorsa T; Ramamurthy NS; Vernillo AT; Zhang X; Konttinen YT; Rifkin BR; Golub LM
J Rheumatol; 1998 May; 25(5):975-82. PubMed ID: 9598901
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulations of matrix metalloproteinase 2: role of the structural metal ions.
Díaz N; Suarez D
Biochemistry; 2007 Aug; 46(31):8943-52. PubMed ID: 17616173
[TBL] [Abstract][Full Text] [Related]
11. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
Acharya MR; Venitz J; Figg WD; Sparreboom A
Drug Resist Updat; 2004 Jun; 7(3):195-208. PubMed ID: 15296861
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines.
Gu Y; Lee HM; Golub LM; Sorsa T; Konttinen YT; Simon SR
Ann Med; 2005; 37(6):450-60. PubMed ID: 16203617
[TBL] [Abstract][Full Text] [Related]
13. Chemically modified tetracyclines induce apoptosis in cultured mast cells.
Sandler C; Nurmi K; Lindstedt KA; Sorsa T; Golub LM; Kovanen PT; Eklund KK
Int Immunopharmacol; 2005 Oct; 5(11):1611-21. PubMed ID: 16039551
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of MMP-13 by chemical modified tetracyclines in osteoblasts.
Kirkwood K; Martin T; Agnello K; Kim YJ
J Int Acad Periodontol; 2004 Apr; 6(2):39-46. PubMed ID: 15125014
[TBL] [Abstract][Full Text] [Related]
15. Peptide hydrolysis catalyzed by matrix metalloproteinase 2: a computational study.
Díaz N; Suárez D
J Phys Chem B; 2008 Jul; 112(28):8412-24. PubMed ID: 18570467
[TBL] [Abstract][Full Text] [Related]
16. In vitro inhibition of matrix metalloproteinase activity in tracheal epithelial lining fluid from horses with recurrent airway obstruction.
Raulo SM; Sorsa T; Maisi P
Am J Vet Res; 2006 Jul; 67(7):1252-7. PubMed ID: 16817751
[TBL] [Abstract][Full Text] [Related]
17. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.
Holmes SG; Still K; Buttle DJ; Bishop NJ; Grabowski PS
Bone; 2004 Aug; 35(2):471-8. PubMed ID: 15268899
[TBL] [Abstract][Full Text] [Related]
18. A novel mechanism of action of chemically modified tetracyclines: inhibition of COX-2-mediated prostaglandin E2 production.
Patel RN; Attur MG; Dave MN; Patel IV; Stuchin SA; Abramson SB; Amin AR
J Immunol; 1999 Sep; 163(6):3459-67. PubMed ID: 10477618
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the molecular structure of the catalytic domain of matrix metalloproteinase-2 in complex with a triple-helical peptide by means of molecular dynamics simulations.
Díaz N; Suárez D; Valdés H
Biochemistry; 2013 Nov; 52(47):8556-69. PubMed ID: 24164447
[TBL] [Abstract][Full Text] [Related]
20. Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.
Gu Y; Lee HM; Simon SR; Golub LM
Pharmacol Res; 2011 Dec; 64(6):595-601. PubMed ID: 21651982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
